Influence of Atazanavir Treatment on Endothelial Dysfunction, Vascular Inflammation and Heme Oxygenase Activity in Type 2 Diabetes Mellitus

Trial Profile

Influence of Atazanavir Treatment on Endothelial Dysfunction, Vascular Inflammation and Heme Oxygenase Activity in Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Atazanavir (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 27 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Jan 2010 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
    • 10 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top